P/B

3.2
Current
11%
More Expensive
vs 3-y average of 2.9

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
3.2
=
Market Cap
$1.6B
/
Total Equity
€551.6m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
3.2
=
Market Cap
$1.6B
/
Total Equity
€551.6m

Valuation Scenarios

Fagron NV is trading above its 3-year average

If P/B returns to its 3-Year Average (2.9), the stock would be worth $23.97 (10% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-64%
Maximum Upside
+9%
Average Downside
18%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 3.2 $26.53
0%
3-Year Average 2.9 $23.97
-10%
5-Year Average 2.9 $24.59
-7%
Industry Average 3.5 $28.92
+9%
Country Average 1.1 $9.53
-64%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

Higher than 89% of companies in Belgium
Percentile
89th
Based on 391 companies
89th percentile
3.5
Low
0.3 — 0.9
Typical Range
0.9 — 1.7
High
1.7 —
Distribution Statistics
Belgium
Min 0.3
30th Percentile 0.9
Median 1.1
70th Percentile 1.7
Max 292.9

Fagron NV
Glance View

Fagron NV is a Belgian multinational company that has woven specialized pharmaceutical compounding into the fabric of modern healthcare. Founded in 1990, the company's mission has always been to advance personalized medicine by focusing on the compounding sector, which involves tailoring and mixing pharmaceutical ingredients to produce unique medications tailored to the specific needs of patients. By transforming individual healthcare demands into bespoke pharmaceutical solutions, Fagron serves the global medical community by manufacturing and distributing both active and inactive pharmaceutical ingredients, as well as offering various base products. This strategic positioning not only supports healthcare professionals and pharmacies in delivering specialized patient care but also fortifies the company's commitment to improving global health outcomes. The key to Fagron's business model lies in its adept integration of innovation alongside therapeutic and technological solutions, ensuring they maintain a strong presence within the compounding market. The company particularly thrives on its ability to address niches in the pharmaceutical industry, ones often overlooked by large pharma entities due to scale inefficiencies. Through its three principal segments—Pharmaceutical Compounding, Raw Materials, and Innovative Concepts—Fagron generates revenue by supplying pharmacies and medical institutions worldwide, from small community pharmacies to large hospital networks. Its broad portfolio of over 30,000 products caters to a spectrum of needs, fostering both patient-specific and bulk pharmaceutical solutions. By combining quality, safety, and regulatory compliance with a keen market understanding, Fagron NV continues to sustain its role as a crucial player in the personalized medicine arena.

ARSUF Intrinsic Value
32.58 USD
Undervaluation 19%
Intrinsic Value
Price $26.53
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett